Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,19451403,half-life,Lenalidomide exhibited a linear pharmacokinetics over a wide range of doses with the mean half-life of 3.9 hours.,Phase I study of oral lenalidomide in patients with refractory metastatic cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19451403/),h,3.9,1887,DB00480,Lenalidomide
,19451403,CL/F,"The renal function affected lenalidomide clearance, resulting in 50% reduction in patients with mild renal impairment compared with patients with normal function (CL/F = 243 mL/min).",Phase I study of oral lenalidomide in patients with refractory metastatic cancer. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19451403/),[ml] / [min],243,1888,DB00480,Lenalidomide
,25594893,flow rate,"Chromatographic separation of analytes was performed on YMC pack ODS AM (150 mm × 4.6 mm, 5 μm) column under gradient conditions with acetonitrile:0.1% formic acid buffer as the mobile phases at a flow rate of 1 ml/min.","Simultaneous quantification of lenalidomide, ibrutinib and its active metabolite PCI-45227 in rat plasma by LC-MS/MS: application to a pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25594893/),[ml] / [min],1,10969,DB00480,Lenalidomide
,25594893,extraction recovery,"Mean extraction recovery for ibrutinib, PCI-45227, lenalidomide and IS of 75.2%, 84.5%, 97.3% and 92.3% were consistent across low, medium, and high QC levels.","Simultaneous quantification of lenalidomide, ibrutinib and its active metabolite PCI-45227 in rat plasma by LC-MS/MS: application to a pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25594893/),%,75.2,10970,DB00480,Lenalidomide
,25594893,extraction recovery,"Mean extraction recovery for ibrutinib, PCI-45227, lenalidomide and IS of 75.2%, 84.5%, 97.3% and 92.3% were consistent across low, medium, and high QC levels.","Simultaneous quantification of lenalidomide, ibrutinib and its active metabolite PCI-45227 in rat plasma by LC-MS/MS: application to a pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25594893/),%,84.5,10971,DB00480,Lenalidomide
,25594893,extraction recovery,"Mean extraction recovery for ibrutinib, PCI-45227, lenalidomide and IS of 75.2%, 84.5%, 97.3% and 92.3% were consistent across low, medium, and high QC levels.","Simultaneous quantification of lenalidomide, ibrutinib and its active metabolite PCI-45227 in rat plasma by LC-MS/MS: application to a pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25594893/),%,97.3,10972,DB00480,Lenalidomide
,25594893,extraction recovery,"Mean extraction recovery for ibrutinib, PCI-45227, lenalidomide and IS of 75.2%, 84.5%, 97.3% and 92.3% were consistent across low, medium, and high QC levels.","Simultaneous quantification of lenalidomide, ibrutinib and its active metabolite PCI-45227 in rat plasma by LC-MS/MS: application to a pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25594893/),%,92.3,10973,DB00480,Lenalidomide
,24486861,extraction recovery,"Pomalidomide was stable in plasma through 4 freeze-thaw cycles (<12% change), in plasma at room temperature for up to 2h for samples not pre-stabilized with 0.1% HCl and up to 8h in samples pre-stabilized with 0.1% HCl, 24h post-preparation at 4°C (<2% change), and showed excellent extraction recovery (∼90%).",A sensitive and robust HPLC assay with fluorescence detection for the quantification of pomalidomide in human plasma for pharmacokinetic analyses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24486861/),%,∼90,20504,DB00480,Lenalidomide
,26337806,T max,Ixazomib was rapidly absorbed with a median T max of 1.5 h on day 1 and 2.0 h on day 15 of cycle 1 and had a geometric mean terminal half-life of 6.1 days.,Pharmacokinetics and safety of ixazomib plus lenalidomide-dexamethasone in Asian patients with relapsed/refractory myeloma: a phase 1 study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26337806/),h,1.5,33350,DB00480,Lenalidomide
,26337806,T max,Ixazomib was rapidly absorbed with a median T max of 1.5 h on day 1 and 2.0 h on day 15 of cycle 1 and had a geometric mean terminal half-life of 6.1 days.,Pharmacokinetics and safety of ixazomib plus lenalidomide-dexamethasone in Asian patients with relapsed/refractory myeloma: a phase 1 study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26337806/),h,2.0,33351,DB00480,Lenalidomide
,26337806,terminal half-life,Ixazomib was rapidly absorbed with a median T max of 1.5 h on day 1 and 2.0 h on day 15 of cycle 1 and had a geometric mean terminal half-life of 6.1 days.,Pharmacokinetics and safety of ixazomib plus lenalidomide-dexamethasone in Asian patients with relapsed/refractory myeloma: a phase 1 study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26337806/),d,6.1,33352,DB00480,Lenalidomide
,23316845,flow rate,"After a simple protein precipitation using methanol, LND and carbamazepine (IS) were separated on Acquity UPLC BEH™ C18 column (50 × 2.1 mm, i.d. 1.7 μm, Waters, USA) using a mobile phase consisted of acetonitrile:water:formic acid (65:35:0.1%, v/v/v) pumped at a flow rate of 0.2 mL/min.",Development and validation of ultra-performance liquid chromatographic method with tandem mass spectrometry for determination of lenalidomide in rabbit and human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23316845/),[ml] / [min],0.2,51317,DB00480,Lenalidomide
,23316845,m/z,"The precursor to product ion transitions of m/z 260.1 > 149.0 and m/z 237.0 > 179.0 were used to quantify LND and IS, respectively.",Development and validation of ultra-performance liquid chromatographic method with tandem mass spectrometry for determination of lenalidomide in rabbit and human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23316845/),,260.1,51318,DB00480,Lenalidomide
>,23316845,m/z,"The precursor to product ion transitions of m/z 260.1 > 149.0 and m/z 237.0 > 179.0 were used to quantify LND and IS, respectively.",Development and validation of ultra-performance liquid chromatographic method with tandem mass spectrometry for determination of lenalidomide in rabbit and human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23316845/),,149.0,51319,DB00480,Lenalidomide
>,23316845,m/z,"The precursor to product ion transitions of m/z 260.1 > 149.0 and m/z 237.0 > 179.0 were used to quantify LND and IS, respectively.",Development and validation of ultra-performance liquid chromatographic method with tandem mass spectrometry for determination of lenalidomide in rabbit and human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23316845/),,237.0,51320,DB00480,Lenalidomide
>,23316845,m/z,"The precursor to product ion transitions of m/z 260.1 > 149.0 and m/z 237.0 > 179.0 were used to quantify LND and IS, respectively.",Development and validation of ultra-performance liquid chromatographic method with tandem mass spectrometry for determination of lenalidomide in rabbit and human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23316845/),,179.0,51321,DB00480,Lenalidomide
,25502411,ΔG(‡),"The enantiomerization barrier ΔG(‡) was determined to be 98.3 ± 1.0 kJ/mol; the activation parameters ΔH(‡) = 46.1 ± 2.4 kJ/mol and ΔS(‡) = -170 ± 61 J/(K·mol) for EM12 and ΔG(‡) = 91.5 ± 1.0 kJ/mol, ΔH(‡) = 62.4 ± 5.4 kJ/mol, and ΔS(‡) = -98 ± 7 J/(K·mol) for lenalidomide.",Investigation of the enantiomerization barriers of the phthalimidone derivatives EM12 and lenalidomide by dynamic electrokinetic chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25502411/),[kj] / [mol],98.3,53431,DB00480,Lenalidomide
,25502411,ΔH(‡),"The enantiomerization barrier ΔG(‡) was determined to be 98.3 ± 1.0 kJ/mol; the activation parameters ΔH(‡) = 46.1 ± 2.4 kJ/mol and ΔS(‡) = -170 ± 61 J/(K·mol) for EM12 and ΔG(‡) = 91.5 ± 1.0 kJ/mol, ΔH(‡) = 62.4 ± 5.4 kJ/mol, and ΔS(‡) = -98 ± 7 J/(K·mol) for lenalidomide.",Investigation of the enantiomerization barriers of the phthalimidone derivatives EM12 and lenalidomide by dynamic electrokinetic chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25502411/),[kj] / [mol],46.1,53432,DB00480,Lenalidomide
,25502411,ΔS(‡),"The enantiomerization barrier ΔG(‡) was determined to be 98.3 ± 1.0 kJ/mol; the activation parameters ΔH(‡) = 46.1 ± 2.4 kJ/mol and ΔS(‡) = -170 ± 61 J/(K·mol) for EM12 and ΔG(‡) = 91.5 ± 1.0 kJ/mol, ΔH(‡) = 62.4 ± 5.4 kJ/mol, and ΔS(‡) = -98 ± 7 J/(K·mol) for lenalidomide.",Investigation of the enantiomerization barriers of the phthalimidone derivatives EM12 and lenalidomide by dynamic electrokinetic chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25502411/),[j] / [k·mol],-170,53433,DB00480,Lenalidomide
,25502411,ΔG(‡),"The enantiomerization barrier ΔG(‡) was determined to be 98.3 ± 1.0 kJ/mol; the activation parameters ΔH(‡) = 46.1 ± 2.4 kJ/mol and ΔS(‡) = -170 ± 61 J/(K·mol) for EM12 and ΔG(‡) = 91.5 ± 1.0 kJ/mol, ΔH(‡) = 62.4 ± 5.4 kJ/mol, and ΔS(‡) = -98 ± 7 J/(K·mol) for lenalidomide.",Investigation of the enantiomerization barriers of the phthalimidone derivatives EM12 and lenalidomide by dynamic electrokinetic chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25502411/),[kj] / [mol],91.5,53434,DB00480,Lenalidomide
,25502411,ΔH(‡),"The enantiomerization barrier ΔG(‡) was determined to be 98.3 ± 1.0 kJ/mol; the activation parameters ΔH(‡) = 46.1 ± 2.4 kJ/mol and ΔS(‡) = -170 ± 61 J/(K·mol) for EM12 and ΔG(‡) = 91.5 ± 1.0 kJ/mol, ΔH(‡) = 62.4 ± 5.4 kJ/mol, and ΔS(‡) = -98 ± 7 J/(K·mol) for lenalidomide.",Investigation of the enantiomerization barriers of the phthalimidone derivatives EM12 and lenalidomide by dynamic electrokinetic chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25502411/),[kj] / [mol],62.4,53435,DB00480,Lenalidomide
,25502411,ΔS(‡),"The enantiomerization barrier ΔG(‡) was determined to be 98.3 ± 1.0 kJ/mol; the activation parameters ΔH(‡) = 46.1 ± 2.4 kJ/mol and ΔS(‡) = -170 ± 61 J/(K·mol) for EM12 and ΔG(‡) = 91.5 ± 1.0 kJ/mol, ΔH(‡) = 62.4 ± 5.4 kJ/mol, and ΔS(‡) = -98 ± 7 J/(K·mol) for lenalidomide.",Investigation of the enantiomerization barriers of the phthalimidone derivatives EM12 and lenalidomide by dynamic electrokinetic chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25502411/),[j] / [k·mol],-98,53436,DB00480,Lenalidomide
,32078124,durations,"In clinical studies, the median durations of the first, second, and subsequent intravenous infusions of daratumumab were 7.0, 4.3, and 3.4 h, respectively.",Split First Dose Administration of Intravenous Daratumumab for the Treatment of Multiple Myeloma (MM): Clinical and Population Pharmacokinetic Analyses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32078124/),,4.3,58493,DB00480,Lenalidomide
,32078124,durations,"In clinical studies, the median durations of the first, second, and subsequent intravenous infusions of daratumumab were 7.0, 4.3, and 3.4 h, respectively.",Split First Dose Administration of Intravenous Daratumumab for the Treatment of Multiple Myeloma (MM): Clinical and Population Pharmacokinetic Analyses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32078124/),,3.4,58494,DB00480,Lenalidomide
,32078124,Kd,"In MMY1001, following administration of the second half of a split first dose on Cycle 1 Day 2, postinfusion median (range) daratumumab concentrations were similar between split first dose [D-Kd, 254.9 (125.8-435.5) µg/ml; D-KRd, 277.2 (164.0-341.8) µg/ml; combined, 256.8 (125.8-435.5) µg/ml] and single first dose [D-Kd, 319.2 (237.5-394.7) µg/ml].",Split First Dose Administration of Intravenous Daratumumab for the Treatment of Multiple Myeloma (MM): Clinical and Population Pharmacokinetic Analyses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32078124/),[μg] / [ml],254.9,58495,DB00480,Lenalidomide
,32078124,D-KRd,"In MMY1001, following administration of the second half of a split first dose on Cycle 1 Day 2, postinfusion median (range) daratumumab concentrations were similar between split first dose [D-Kd, 254.9 (125.8-435.5) µg/ml; D-KRd, 277.2 (164.0-341.8) µg/ml; combined, 256.8 (125.8-435.5) µg/ml] and single first dose [D-Kd, 319.2 (237.5-394.7) µg/ml].",Split First Dose Administration of Intravenous Daratumumab for the Treatment of Multiple Myeloma (MM): Clinical and Population Pharmacokinetic Analyses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32078124/),[μg] / [ml],277.2,58496,DB00480,Lenalidomide
,32078124,D-KRd,"In MMY1001, following administration of the second half of a split first dose on Cycle 1 Day 2, postinfusion median (range) daratumumab concentrations were similar between split first dose [D-Kd, 254.9 (125.8-435.5) µg/ml; D-KRd, 277.2 (164.0-341.8) µg/ml; combined, 256.8 (125.8-435.5) µg/ml] and single first dose [D-Kd, 319.2 (237.5-394.7) µg/ml].",Split First Dose Administration of Intravenous Daratumumab for the Treatment of Multiple Myeloma (MM): Clinical and Population Pharmacokinetic Analyses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32078124/),[μg] / [ml],256.8,58497,DB00480,Lenalidomide
,32078124,D-Kd,"In MMY1001, following administration of the second half of a split first dose on Cycle 1 Day 2, postinfusion median (range) daratumumab concentrations were similar between split first dose [D-Kd, 254.9 (125.8-435.5) µg/ml; D-KRd, 277.2 (164.0-341.8) µg/ml; combined, 256.8 (125.8-435.5) µg/ml] and single first dose [D-Kd, 319.2 (237.5-394.7) µg/ml].",Split First Dose Administration of Intravenous Daratumumab for the Treatment of Multiple Myeloma (MM): Clinical and Population Pharmacokinetic Analyses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32078124/),[μg] / [ml],319.2,58498,DB00480,Lenalidomide
,32078124,D-KRd,"At the end of weekly dosing, median (range) Cycle 3 Day 1 preinfusion daratumumab concentrations were similar between split first dose [D-Kd, 663.9 (57.7-1110.7) µg/ml; D-KRd, 575.1 (237.9-825.5) µg/ml; combined, 639.2 (57.7-1110.7) µg/ml] and single first dose [D-Kd, 463.2 (355.9-792.9) µg/ml].",Split First Dose Administration of Intravenous Daratumumab for the Treatment of Multiple Myeloma (MM): Clinical and Population Pharmacokinetic Analyses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32078124/),[μg] / [ml],575.1,58499,DB00480,Lenalidomide
,32078124,D-KRd,"At the end of weekly dosing, median (range) Cycle 3 Day 1 preinfusion daratumumab concentrations were similar between split first dose [D-Kd, 663.9 (57.7-1110.7) µg/ml; D-KRd, 575.1 (237.9-825.5) µg/ml; combined, 639.2 (57.7-1110.7) µg/ml] and single first dose [D-Kd, 463.2 (355.9-792.9) µg/ml].",Split First Dose Administration of Intravenous Daratumumab for the Treatment of Multiple Myeloma (MM): Clinical and Population Pharmacokinetic Analyses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32078124/),[μg] / [ml],639.2,58500,DB00480,Lenalidomide
,32078124,D-Kd,"At the end of weekly dosing, median (range) Cycle 3 Day 1 preinfusion daratumumab concentrations were similar between split first dose [D-Kd, 663.9 (57.7-1110.7) µg/ml; D-KRd, 575.1 (237.9-825.5) µg/ml; combined, 639.2 (57.7-1110.7) µg/ml] and single first dose [D-Kd, 463.2 (355.9-792.9) µg/ml].",Split First Dose Administration of Intravenous Daratumumab for the Treatment of Multiple Myeloma (MM): Clinical and Population Pharmacokinetic Analyses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32078124/),[μg] / [ml],463.2,58501,DB00480,Lenalidomide
<,20160158,maximal drug content,The maximal drug content in a single ejaculate was <2000 ng (<0.01% of the daily 25-mg dose).,Distribution of lenalidomide into semen of healthy men after multiple oral doses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20160158/),ng,2000,61318,DB00480,Lenalidomide
,22955172,time to C (max) (t (max)),"Co-administration with a high-fat meal reduced the area under the concentration-time curve (AUC) and C (max) by approximately 20 and 50 %, respectively, and delayed time to C (max) (t (max)) by 1.63 h.","Single-dose pharmacokinetics of lenalidomide in healthy volunteers: dose proportionality, food effect, and racial sensitivity. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22955172/),h,1.63,71582,DB00480,Lenalidomide
,22955172,terminal elimination half-life (t (½)),The terminal elimination half-life (t (½)) was 3-4 h at doses up to 50 mg and was not affected by food.,"Single-dose pharmacokinetics of lenalidomide in healthy volunteers: dose proportionality, food effect, and racial sensitivity. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22955172/),h,3-4,71583,DB00480,Lenalidomide
,27988790,area under the curve,"According to our model, the area under the curve was 3273 µg h/L, i.e., 60% higher than expected under usual dosage (25 mg q.d.) with normal renal function.",Pharmacokinetics of lenalidomide during high cut-off dialysis in a patient with multiple myeloma and renal failure. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27988790/),[h·μg] / [l],3273,91471,DB00480,Lenalidomide
,31089832,AUC0-24,"AUC0-24 was significantly higher in patients with the T allele of 3435C>T (n = 15) than in those without (n = 21) (median 6324.6 ng h/mL vs. 2857.4 ng h/mL, p = 0.028).",Influence of ABCB1 polymorphisms on the pharmacokinetics and toxicity of lenalidomide in patients with multiple myeloma. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31089832/),[h·ng] / [ml],6324.6,94584,DB00480,Lenalidomide
,31089832,AUC0-24,"AUC0-24 was significantly higher in patients with the T allele of 3435C>T (n = 15) than in those without (n = 21) (median 6324.6 ng h/mL vs. 2857.4 ng h/mL, p = 0.028).",Influence of ABCB1 polymorphisms on the pharmacokinetics and toxicity of lenalidomide in patients with multiple myeloma. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31089832/),[h·ng] / [ml],2857.4,94585,DB00480,Lenalidomide
,30117017,time to reach maximum plasma concentration,"Ixazomib absorption is rapid, with a median time to reach maximum plasma concentration of approximately 1 h post-dose.",Clinical Pharmacology of Ixazomib: The First Oral Proteasome Inhibitor. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30117017/),h,1,102068,DB00480,Lenalidomide
,30117017,terminal half-life,Ixazomib pharmacokinetics (PK) are adequately described by a three-compartment model (terminal half-life of 9.5 days) with first-order linear absorption (oral bioavailability of 58%).,Clinical Pharmacology of Ixazomib: The First Oral Proteasome Inhibitor. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30117017/),d,9.5,102069,DB00480,Lenalidomide
,30117017,oral bioavailability,Ixazomib pharmacokinetics (PK) are adequately described by a three-compartment model (terminal half-life of 9.5 days) with first-order linear absorption (oral bioavailability of 58%).,Clinical Pharmacology of Ixazomib: The First Oral Proteasome Inhibitor. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30117017/),%,58,102070,DB00480,Lenalidomide
,24463402,flow rate,"Analytes were recovered by liquid-liquid extraction and separated on a reverse phase C18 column (150mm×4.6mm i.d., 5μm) using methanol:0.1% formic acid buffer (70:30) as mobile phase at a flow rate of 1mL/min in isocratic mode.","Simultaneous quantification of idelalisib, fludarabine and lenalidomide in rat plasma by using high-performance liquid chromatography coupled with heated electrospray ionization tandem mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24463402/),[ml] / [min],1,103646,DB00480,Lenalidomide
,22956478,systemic bioavailability,"Administration of 0.5 and 10 mg/kg resulted in systemic bioavailability ranges of 90-105% and 60-75% via IP and oral routes, respectively.",Pharmacokinetics and tissue disposition of lenalidomide in mice. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22956478/),%,90-105,115790,DB00480,Lenalidomide
,22956478,systemic bioavailability,"Administration of 0.5 and 10 mg/kg resulted in systemic bioavailability ranges of 90-105% and 60-75% via IP and oral routes, respectively.",Pharmacokinetics and tissue disposition of lenalidomide in mice. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22956478/),%,60-75,115791,DB00480,Lenalidomide
,33075165,ORR,"The ORR in patients with NHL (n = 13) was 54%, including four complete and three partial responses.","Phase I, multicenter, dose-escalation study of avadomide in adult Japanese patients with advanced malignancies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33075165/),%,54,119779,DB00480,Lenalidomide
<,18056189,time to tumor progression,"In the group of 24 patients with recurrent glioblastoma, the median time to tumor progression was <2 months and only 12.5% of patients were progression-free at 6 months.",A phase I trial of lenalidomide in patients with recurrent primary central nervous system tumors. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18056189/),month,2,125862,DB00480,Lenalidomide
,20956622,Response duration,Response duration ranged from 5.6 to 14 months.,Dose escalation of lenalidomide in relapsed or refractory acute leukemias. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20956622/),month,5.6 to 14,128705,DB00480,Lenalidomide
,28290121,terminal disposition phase half-life,"The geometric mean terminal disposition phase half-life was 9.5 days, steady-state volume of distribution was 543 L and systemic clearance was 1.86 L/h.","Population Pharmacokinetic Analysis of Ixazomib, an Oral Proteasome Inhibitor, Including Data from the Phase III TOURMALINE-MM1 Study to Inform Labelling. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28290121/),d,9.5,147189,DB00480,Lenalidomide
,28290121,steady-state volume of distribution,"The geometric mean terminal disposition phase half-life was 9.5 days, steady-state volume of distribution was 543 L and systemic clearance was 1.86 L/h.","Population Pharmacokinetic Analysis of Ixazomib, an Oral Proteasome Inhibitor, Including Data from the Phase III TOURMALINE-MM1 Study to Inform Labelling. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28290121/),l,543,147190,DB00480,Lenalidomide
,28290121,systemic clearance,"The geometric mean terminal disposition phase half-life was 9.5 days, steady-state volume of distribution was 543 L and systemic clearance was 1.86 L/h.","Population Pharmacokinetic Analysis of Ixazomib, an Oral Proteasome Inhibitor, Including Data from the Phase III TOURMALINE-MM1 Study to Inform Labelling. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28290121/),[l] / [h],1.86,147191,DB00480,Lenalidomide
,28290121,absolute bioavailability,The absolute bioavailability of an oral dose was estimated to be 58%.,"Population Pharmacokinetic Analysis of Ixazomib, an Oral Proteasome Inhibitor, Including Data from the Phase III TOURMALINE-MM1 Study to Inform Labelling. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28290121/),%,58,147192,DB00480,Lenalidomide
,22936658,response rate,"Among 39 patients, HI-E response rate to monotherapy was 86% (6 of 7) in del(5q) and 25% (8 of 32) in non-del(5q) patients (10 mg, 17.7%; 15 mg, 33.3%).",Combined treatment with lenalidomide and epoetin alfa in lower-risk patients with myelodysplastic syndrome. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22936658/),%,86,150736,DB00480,Lenalidomide
,22936658,response rate,"Among 39 patients, HI-E response rate to monotherapy was 86% (6 of 7) in del(5q) and 25% (8 of 32) in non-del(5q) patients (10 mg, 17.7%; 15 mg, 33.3%).",Combined treatment with lenalidomide and epoetin alfa in lower-risk patients with myelodysplastic syndrome. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22936658/),%,25,150737,DB00480,Lenalidomide
,22109830,apparent clearance (Cl/F),"For thalidomide, the median apparent clearance (Cl/F) was 2.9 mL/min/kg, the median plasma AUC was 80 μM h, and the median terminal half-life (t(½)) was 13.3 h.",Plasma and cerebrospinal fluid pharmacokinetics of thalidomide and lenalidomide in nonhuman primates. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22109830/),[ml] / [kg·min],2.9,158779,DB00480,Lenalidomide
,22109830,plasma AUC,"For thalidomide, the median apparent clearance (Cl/F) was 2.9 mL/min/kg, the median plasma AUC was 80 μM h, and the median terminal half-life (t(½)) was 13.3 h.",Plasma and cerebrospinal fluid pharmacokinetics of thalidomide and lenalidomide in nonhuman primates. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22109830/),h·μM,80,158780,DB00480,Lenalidomide
,22109830,terminal half-life (t(½)),"For thalidomide, the median apparent clearance (Cl/F) was 2.9 mL/min/kg, the median plasma AUC was 80 μM h, and the median terminal half-life (t(½)) was 13.3 h.",Plasma and cerebrospinal fluid pharmacokinetics of thalidomide and lenalidomide in nonhuman primates. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22109830/),h,13.3,158781,DB00480,Lenalidomide
,22109830,Cl/F,"For lenalidomide, the median Cl/F was 8.7 mL/min/kg, the median AUC was 9 μM h, and the median t(½) was 5.6 h.",Plasma and cerebrospinal fluid pharmacokinetics of thalidomide and lenalidomide in nonhuman primates. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22109830/),[ml] / [kg·min],8.7,158782,DB00480,Lenalidomide
,22109830,AUC,"For lenalidomide, the median Cl/F was 8.7 mL/min/kg, the median AUC was 9 μM h, and the median t(½) was 5.6 h.",Plasma and cerebrospinal fluid pharmacokinetics of thalidomide and lenalidomide in nonhuman primates. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22109830/),h·μM,9,158783,DB00480,Lenalidomide
,22109830,t(½),"For lenalidomide, the median Cl/F was 8.7 mL/min/kg, the median AUC was 9 μM h, and the median t(½) was 5.6 h.",Plasma and cerebrospinal fluid pharmacokinetics of thalidomide and lenalidomide in nonhuman primates. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22109830/),h,5.6,158784,DB00480,Lenalidomide
,22109830,penetration,"Thalidomide was detected in the CSF of all animals, with a median penetration of 42%.",Plasma and cerebrospinal fluid pharmacokinetics of thalidomide and lenalidomide in nonhuman primates. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22109830/),%,42,158785,DB00480,Lenalidomide
,22109830,penetration,"Lenalidomide was detected in the CSF of 2 of 3 animals, with a CSF penetration of 11% in each.",Plasma and cerebrospinal fluid pharmacokinetics of thalidomide and lenalidomide in nonhuman primates. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22109830/),%,11,158786,DB00480,Lenalidomide
,29938772,overall response rate,"In 62 evaluable patients, the confirmed overall response rate was 94% (68% ≥very good partial response; 24% complete response).",Twice-weekly ixazomib in combination with lenalidomide-dexamethasone in patients with newly diagnosed multiple myeloma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29938772/),%,94,164466,DB00480,Lenalidomide
,29938772,progression-free survival,Median progression-free survival was 24·9 months.,Twice-weekly ixazomib in combination with lenalidomide-dexamethasone in patients with newly diagnosed multiple myeloma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29938772/),month,24·9,164467,DB00480,Lenalidomide
,28000099,T max,"Ixazomib was rapidly absorbed with a median T max of approximately 1-2-h post-dose, and had a geometric mean terminal half-life of 5-6 days.",Phase 1 study of ixazomib alone or combined with lenalidomide-dexamethasone in Japanese patients with relapsed/refractory multiple myeloma. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28000099/),h,1-2-,164685,DB00480,Lenalidomide
,28000099,terminal half-life,"Ixazomib was rapidly absorbed with a median T max of approximately 1-2-h post-dose, and had a geometric mean terminal half-life of 5-6 days.",Phase 1 study of ixazomib alone or combined with lenalidomide-dexamethasone in Japanese patients with relapsed/refractory multiple myeloma. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28000099/),d,5-6,164686,DB00480,Lenalidomide
,33040274,RP2D,The RP2D of lenalidomide administered daily during radiation therapy is 116 mg/m2/day.,A phase I trial of lenalidomide and radiotherapy in children with diffuse intrinsic pontine gliomas or high-grade gliomas. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33040274/),[mg] / [d·m2],116,178932,DB00480,Lenalidomide
,30672004,apparent clearance,"The population parameter estimates for apparent clearance, apparent volume of distribution and transit rate constant were 12 L/h (10.8-13.6), 68.8 L (61.8-76.3), and 13.5 h-1 (11.9-36.8) respectively.",Population pharmacokinetics of lenalidomide in patients with B-cell malignancies. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30672004/),[l] / [h],12,181214,DB00480,Lenalidomide
,30672004,apparent volume of distribution,"The population parameter estimates for apparent clearance, apparent volume of distribution and transit rate constant were 12 L/h (10.8-13.6), 68.8 L (61.8-76.3), and 13.5 h-1 (11.9-36.8) respectively.",Population pharmacokinetics of lenalidomide in patients with B-cell malignancies. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30672004/),l,68.8,181215,DB00480,Lenalidomide
,30672004,transit rate constant,"The population parameter estimates for apparent clearance, apparent volume of distribution and transit rate constant were 12 L/h (10.8-13.6), 68.8 L (61.8-76.3), and 13.5 h-1 (11.9-36.8) respectively.",Population pharmacokinetics of lenalidomide in patients with B-cell malignancies. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30672004/),1/[h],13.5,181216,DB00480,Lenalidomide
,26795075,CrCl,"The median baseline CrCl was 105 mL/min (range, 84-146 mL/min) for those with NRF and 26 mL/min (range, 15-33 mL/min) for those with SRI.",Pharmacokinetics and Safety of Elotuzumab Combined With Lenalidomide and Dexamethasone in Patients With Multiple Myeloma and Various Levels of Renal Impairment: Results of a Phase Ib Study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26795075/),[ml] / [min],105,184705,DB00480,Lenalidomide
,26795075,CrCl,"The median baseline CrCl was 105 mL/min (range, 84-146 mL/min) for those with NRF and 26 mL/min (range, 15-33 mL/min) for those with SRI.",Pharmacokinetics and Safety of Elotuzumab Combined With Lenalidomide and Dexamethasone in Patients With Multiple Myeloma and Various Levels of Renal Impairment: Results of a Phase Ib Study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26795075/),[ml] / [min],26,184706,DB00480,Lenalidomide
,26795075,overall response rates,"The overall response rates were 75% in the NRF, 67% in the SRI, and 56% in the ESRD groups.",Pharmacokinetics and Safety of Elotuzumab Combined With Lenalidomide and Dexamethasone in Patients With Multiple Myeloma and Various Levels of Renal Impairment: Results of a Phase Ib Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26795075/),%,75,184707,DB00480,Lenalidomide
,26795075,overall response rates,"The overall response rates were 75% in the NRF, 67% in the SRI, and 56% in the ESRD groups.",Pharmacokinetics and Safety of Elotuzumab Combined With Lenalidomide and Dexamethasone in Patients With Multiple Myeloma and Various Levels of Renal Impairment: Results of a Phase Ib Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26795075/),%,67,184708,DB00480,Lenalidomide
,26795075,overall response rates,"The overall response rates were 75% in the NRF, 67% in the SRI, and 56% in the ESRD groups.",Pharmacokinetics and Safety of Elotuzumab Combined With Lenalidomide and Dexamethasone in Patients With Multiple Myeloma and Various Levels of Renal Impairment: Results of a Phase Ib Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26795075/),%,56,184709,DB00480,Lenalidomide
,23497635,flow rate,"Separation of the derivatized LND was performed on Hypersil BDS C18 column (250 × 4.6 mm, 5 μm particle size) using a mobile phase consisting of phosphate buffer (pH 4):methanol: tetrahydrofuran (70:10:20, v/v) at a flow rate of 1.0 mL/min.",Trace determination of lenalidomide in plasma by non-extractive HPLC procedures with fluorescence detection after pre-column derivatization with fluorescamine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23497635/),[ml] / [min],1.0,185910,DB00480,Lenalidomide
,23497635,limits of detection,"The limits of detection and quantitation were 0.8 and 2.30 ng/mL, respectively.",Trace determination of lenalidomide in plasma by non-extractive HPLC procedures with fluorescence detection after pre-column derivatization with fluorescamine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23497635/),[ng] / [ml],0.8,185911,DB00480,Lenalidomide
,23497635,limits of detection,"The limits of detection and quantitation were 0.8 and 2.30 ng/mL, respectively.",Trace determination of lenalidomide in plasma by non-extractive HPLC procedures with fluorescence detection after pre-column derivatization with fluorescamine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23497635/),[ng] / [ml],2.30,185912,DB00480,Lenalidomide
,23497635,recovery,The recovery of LND from the spiked human plasma was 99.30 ± 2.88.,Trace determination of lenalidomide in plasma by non-extractive HPLC procedures with fluorescence detection after pre-column derivatization with fluorescamine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23497635/),,99.30,185913,DB00480,Lenalidomide
,21825263,MTD,"The MTD of this combination regimen was 25 mg lenalidomide with 15 mg CCI-779, with toxicities of fatigue, neutropenia, and electrolyte wasting.",Phase I trial of lenalidomide and CCI-779 in patients with relapsed multiple myeloma: evidence for lenalidomide-CCI-779 interaction via P-glycoprotein. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21825263/),mg,25,191723,DB00480,Lenalidomide
,17954615,t((1/2)),"As renal impairment progressed to moderate, severe, or end-stage renal disease, total and renal lenalidomide clearance decreased drastically, area under the concentration-time curve increased by approximately 185% to 420%, and t((1/2)) was prolonged by approximately 6 to 12 hours.",Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17954615/),h,6,193487,DB00480,Lenalidomide
,16840727,Overall response rate,"Overall response rate (complete, partial, or minor) to lenalidomide alone was 25% (24% for once-daily and 29% for twice-daily lenalidomide).",A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16840727/),%,25,194061,DB00480,Lenalidomide
,16840727,Overall response rate,"Overall response rate (complete, partial, or minor) to lenalidomide alone was 25% (24% for once-daily and 29% for twice-daily lenalidomide).",A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16840727/),%,24,194062,DB00480,Lenalidomide
,16840727,Overall response rate,"Overall response rate (complete, partial, or minor) to lenalidomide alone was 25% (24% for once-daily and 29% for twice-daily lenalidomide).",A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16840727/),%,29,194063,DB00480,Lenalidomide
,16840727,overall survival,"Median overall survival in 30-mg once-daily and twice-daily groups was 28 and 27 months, respectively.",A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16840727/),month,28,194064,DB00480,Lenalidomide
,16840727,overall survival,"Median overall survival in 30-mg once-daily and twice-daily groups was 28 and 27 months, respectively.",A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16840727/),month,27,194065,DB00480,Lenalidomide
,16840727,progression-free survival,Median progression-free survival was 7.7 months on once-daily versus 3.9 months on twice-daily lenalidomide (P = .2).,A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16840727/),month,7.7,194066,DB00480,Lenalidomide
,16840727,progression-free survival,Median progression-free survival was 7.7 months on once-daily versus 3.9 months on twice-daily lenalidomide (P = .2).,A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16840727/),month,3.9,194067,DB00480,Lenalidomide
,16840727,Time to first occurrence,"Time to first occurrence of clinically significant grade 3/4 myelosuppression was shorter in the twice-daily group (1.8 vs 5.5 months, P = .05).",A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16840727/),month,1.8,194068,DB00480,Lenalidomide
,16840727,Time to first occurrence,"Time to first occurrence of clinically significant grade 3/4 myelosuppression was shorter in the twice-daily group (1.8 vs 5.5 months, P = .05).",A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16840727/),month,5.5,194069,DB00480,Lenalidomide
,26956578,flow rate,"Separation of lenalidomide was performed on an Xterra RP C18 (250 mm length × 4.6 mm i.d., 5 µm) using a mobile phase consisting of phosphate buffer/acetonitrile (85:15, v/v, pH 3.2) at a flow rate of 0.5 mL · min-1 The samples were monitored at a wavelength of 311 nm.",A Wide Linearity Range Method for the Determination of Lenalidomide in Plasma by High-Performance Liquid Chromatography: Application to Pharmacokinetic Studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26956578/),[ml] / [min],0.5,201465,DB00480,Lenalidomide
,26956578,limits of,"A linear relationship with good correlation coefficient (r = 0.997, n = 9) was found between the peak area and lenalidomide concentrations in the range of 100 to 950 ng · mL-1 The limits of detection and quantitation were 28 and 100 ng · mL-1, respectively.",A Wide Linearity Range Method for the Determination of Lenalidomide in Plasma by High-Performance Liquid Chromatography: Application to Pharmacokinetic Studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26956578/),[ng] / [ml],28,201466,DB00480,Lenalidomide
,27848182,durations,Maximum (median) durations of study therapy were 36.6 (35.2) months in Cohort 1 and 28.3 (9.2) months in Cohort 2.,Elotuzumab with lenalidomide and dexamethasone for Japanese patients with relapsed/refractory multiple myeloma: phase 1 study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27848182/),month,36.6,201723,DB00480,Lenalidomide
,27848182,durations,Maximum (median) durations of study therapy were 36.6 (35.2) months in Cohort 1 and 28.3 (9.2) months in Cohort 2.,Elotuzumab with lenalidomide and dexamethasone for Japanese patients with relapsed/refractory multiple myeloma: phase 1 study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27848182/),month,28.3,201724,DB00480,Lenalidomide
,27848182,Overall response,"Overall response was 83% (n = 5): one complete response, three very good partial responses, one partial response.",Elotuzumab with lenalidomide and dexamethasone for Japanese patients with relapsed/refractory multiple myeloma: phase 1 study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27848182/),%,83,201725,DB00480,Lenalidomide
,15522712,flow rate,"Separation of the compounds of interest was achieved on a column packed with Waters C18 Nova-Pak material (4 microm particle size; 300 mm x 3.9 mm internal diameter) using acetonitrile, de-ionized water, and glacial acetic acid in ratios of 20:80:0.1 (v/v/v) (pH 3.5) delivered at an isocratic flow rate of 1.00 ml/min.","Determination of CC-5013, an analogue of thalidomide, in human plasma by liquid chromatography-mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15522712/),[ml] / [min],1.00,207890,DB00480,Lenalidomide
,27085994,progression-free survival,"The median progression-free survival and overall survival were 2.8 and 5.5 months, respectively.",Phase I clinical trial of lenalidomide in combination with bevacizumab in patients with advanced cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27085994/),month,2.8,215210,DB00480,Lenalidomide
,27085994,overall survival,"The median progression-free survival and overall survival were 2.8 and 5.5 months, respectively.",Phase I clinical trial of lenalidomide in combination with bevacizumab in patients with advanced cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27085994/),month,5.5,215211,DB00480,Lenalidomide
,28483761,overall response rate (ORR),"In the efficacy-evaluable population, the overall response rate (ORR) was 56% (29/52) and was similar between the 10 mg/kg Q2W and 10 and 20 mg/kg QW/Q2W cohorts.",A phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed/refractory multiple myeloma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28483761/),%,56,219599,DB00480,Lenalidomide
,28483761,progression-free survival,Overall median progression-free survival was 8.5 months.,A phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed/refractory multiple myeloma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28483761/),month,8.5,219600,DB00480,Lenalidomide
,24295177,limit of detection,The assay limit of detection was 0.05 ng/mL and the effective working range at relative standard deviations (RSD) of ≤5% was 0.1-20 ng/mL.,A highly sensitive polyclonal antibody-based ELISA for therapeutic monitoring and pharmacokinetic studies of lenalidomide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24295177/),[ng] / [ml],0.05,231880,DB00480,Lenalidomide
,24295177,Analytical recovery,Analytical recovery of LND from spiked plasma was 100.98 ± 3.05.,A highly sensitive polyclonal antibody-based ELISA for therapeutic monitoring and pharmacokinetic studies of lenalidomide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24295177/),,100.98,231881,DB00480,Lenalidomide
,20559759,overall response rate,"In the combination cohort, the overall response rate (> or =PR) was 100%.",Lenalidomide plus dexamethasone treatment in Japanese patients with relapsed/refractory multiple myeloma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20559759/),%,100,233350,DB00480,Lenalidomide
,29076150,overall response rate,"The overall response rate and clinical benefit rate was 53% (19/36) and 64% (23/36), respectively.","A phase 1 clinical trial evaluating marizomib, pomalidomide and low-dose dexamethasone in relapsed and refractory multiple myeloma (NPI-0052-107): final study results. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29076150/),%,53,241002,DB00480,Lenalidomide
,29076150,clinical benefit rate,"The overall response rate and clinical benefit rate was 53% (19/36) and 64% (23/36), respectively.","A phase 1 clinical trial evaluating marizomib, pomalidomide and low-dose dexamethasone in relapsed and refractory multiple myeloma (NPI-0052-107): final study results. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29076150/),%,64,241003,DB00480,Lenalidomide
,22037879,T (max),"Metabolite profiling and quantitation were accomplished using liquid chromatography with mass spectrometric and radiochemical detection. [(14)C]-Lenalidomide was rapidly absorbed (T (max) 0.77-1.0 h), and the levels declined with a terminal half-life of approximately 3 h, with similar profiles for total blood and plasma radioactivity as well as plasma lenalidomide.","Pharmacokinetics, metabolism and excretion of [(14)C]-lenalidomide following oral administration in healthy male subjects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22037879/),h,0.77-1.0,241572,DB00480,Lenalidomide
,22037879,terminal half-life,"Metabolite profiling and quantitation were accomplished using liquid chromatography with mass spectrometric and radiochemical detection. [(14)C]-Lenalidomide was rapidly absorbed (T (max) 0.77-1.0 h), and the levels declined with a terminal half-life of approximately 3 h, with similar profiles for total blood and plasma radioactivity as well as plasma lenalidomide.","Pharmacokinetics, metabolism and excretion of [(14)C]-lenalidomide following oral administration in healthy male subjects. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22037879/),h,3,241573,DB00480,Lenalidomide
,24920586,maximum tolerated dose,"The maximum tolerated dose was 2.0 mg/m(2), which 40 patients received in 4 expansion cohorts.","Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24920586/),[mg] / [m(2],2.0,242784,DB00480,Lenalidomide
,24920586,terminal half-life,The terminal half-life of ixazomib was 3.3 to 7.4 days; plasma exposure increased proportionally with dose (0.48-2.23 mg/m(2)).,"Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patients. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24920586/),d,3.3 to 7.4,242785,DB00480,Lenalidomide
,23364621,overall response rate,"Although nearly 50% of patients were refractory to both bortezomib and lenalidomide, end of study partial response or better (overall response rate) was 25.5% with 7.9 months median duration of response.",Carfilzomib in multiple myeloma patients with renal impairment: pharmacokinetics and safety. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23364621/),,25.5,248829,DB00480,Lenalidomide
,23782711,disease control rate,"In the efficacy population (n = 187), the disease control rate (at least stable disease) was 94.7%, and the overall response rate (at least partial response) was 47.6%.","A multicenter, open-label, phase 2 study of lenalidomide plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma: the MM-021 trial. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23782711/),%,94.,250339,DB00480,Lenalidomide
,23782711,overall response rate,"In the efficacy population (n = 187), the disease control rate (at least stable disease) was 94.7%, and the overall response rate (at least partial response) was 47.6%.","A multicenter, open-label, phase 2 study of lenalidomide plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma: the MM-021 trial. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23782711/),%,47.6,250340,DB00480,Lenalidomide
,23782711,response duration,"After a median study follow-up of 15.2 months, the median response duration was 8.8 months (range, 0.4-18.8 months) and median progression-free survival was 8.3 months (95% CI 6.5-9.8).","A multicenter, open-label, phase 2 study of lenalidomide plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma: the MM-021 trial. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23782711/),month,8.8,250341,DB00480,Lenalidomide
,23782711,progression-free survival,"After a median study follow-up of 15.2 months, the median response duration was 8.8 months (range, 0.4-18.8 months) and median progression-free survival was 8.3 months (95% CI 6.5-9.8).","A multicenter, open-label, phase 2 study of lenalidomide plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma: the MM-021 trial. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23782711/),month,8.3,250342,DB00480,Lenalidomide
,27286995,Overall response,"Overall response was 76 %, and safety profiles were similar across groups, with no exposure-dependent trend in efficacy or toxicity.","Pharmacokinetics, safety, and efficacy of lenalidomide plus dexamethasone in patients with multiple myeloma and renal impairment. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27286995/),%,76,261754,DB00480,Lenalidomide
,32874573,plasma concentrations,"Patient 1 had plasma concentrations of ixazomib averaging 26.2, 21.8 and 15.3 ng/ml at incision, tumor sampling and closure, respectively.",A phase 0 analysis of ixazomib in patients with glioblastoma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32874573/),[ng] / [ml],26.2,263413,DB00480,Lenalidomide
,32874573,plasma concentrations,"Patient 1 had plasma concentrations of ixazomib averaging 26.2, 21.8 and 15.3 ng/ml at incision, tumor sampling and closure, respectively.",A phase 0 analysis of ixazomib in patients with glioblastoma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32874573/),[ng] / [ml],21.8,263414,DB00480,Lenalidomide
,32874573,plasma concentrations,"Patient 1 had plasma concentrations of ixazomib averaging 26.2, 21.8 and 15.3 ng/ml at incision, tumor sampling and closure, respectively.",A phase 0 analysis of ixazomib in patients with glioblastoma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32874573/),[ng] / [ml],15.3,263415,DB00480,Lenalidomide
,32874573,brain tumor tissue concentration,The brain tumor tissue concentration was 7.88 ng/g.,A phase 0 analysis of ixazomib in patients with glioblastoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32874573/),[ng] / [g],7.88,263416,DB00480,Lenalidomide
,32874573,plasma concentration interval,"Patient 3 had plasma concentration interval measurements of 25.6, 36.2 and 28.7 ng/ml.",A phase 0 analysis of ixazomib in patients with glioblastoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32874573/),[ng] / [ml],25.6,263417,DB00480,Lenalidomide
,32874573,plasma concentration interval,"Patient 3 had plasma concentration interval measurements of 25.6, 36.2 and 28.7 ng/ml.",A phase 0 analysis of ixazomib in patients with glioblastoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32874573/),[ng] / [ml],36.2,263418,DB00480,Lenalidomide
,32874573,plasma concentration interval,"Patient 3 had plasma concentration interval measurements of 25.6, 36.2 and 28.7 ng/ml.",A phase 0 analysis of ixazomib in patients with glioblastoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32874573/),[ng] / [ml],28.7,263419,DB00480,Lenalidomide
,27531679,overall response rate,"In part 2 (median follow-up of 15.6 months), overall response rate was 81%, with 8 stringent complete responses (25%), 3 complete responses (9%), and 9 very good partial responses (28%).","Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27531679/),%,81,263453,DB00480,Lenalidomide
,29926217,Cmax,"Subjects administered test lenalidomide and Revlimid® capsules in the fasting state had a Cmax of 564 ± 153 and 609 ± 121 ng/mL, respectively; an AUC0-t of 1660 ± 211 and 1660 ± 235 h ng/mL, respectively; and an AUC0-∞ of 1670 ± 210 and 1670 ± 237 h ng/mL, respectively.",Bioequivalence study of single-dose lenalidomide capsule vs. Revlimid® capsule in healthy Chinese males. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29926217/),[ng] / [ml],564,264204,DB00480,Lenalidomide
,29926217,Cmax,"Subjects administered test lenalidomide and Revlimid® capsules in the fasting state had a Cmax of 564 ± 153 and 609 ± 121 ng/mL, respectively; an AUC0-t of 1660 ± 211 and 1660 ± 235 h ng/mL, respectively; and an AUC0-∞ of 1670 ± 210 and 1670 ± 237 h ng/mL, respectively.",Bioequivalence study of single-dose lenalidomide capsule vs. Revlimid® capsule in healthy Chinese males. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29926217/),[ng] / [ml],609,264205,DB00480,Lenalidomide
,29926217,AUC0-t,"Subjects administered test lenalidomide and Revlimid® capsules in the fasting state had a Cmax of 564 ± 153 and 609 ± 121 ng/mL, respectively; an AUC0-t of 1660 ± 211 and 1660 ± 235 h ng/mL, respectively; and an AUC0-∞ of 1670 ± 210 and 1670 ± 237 h ng/mL, respectively.",Bioequivalence study of single-dose lenalidomide capsule vs. Revlimid® capsule in healthy Chinese males. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29926217/),[h·ng] / [ml],1660,264206,DB00480,Lenalidomide
,29926217,AUC0-t,"Subjects administered test lenalidomide and Revlimid® capsules in the fasting state had a Cmax of 564 ± 153 and 609 ± 121 ng/mL, respectively; an AUC0-t of 1660 ± 211 and 1660 ± 235 h ng/mL, respectively; and an AUC0-∞ of 1670 ± 210 and 1670 ± 237 h ng/mL, respectively.",Bioequivalence study of single-dose lenalidomide capsule vs. Revlimid® capsule in healthy Chinese males. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29926217/),[h·ng] / [ml],1660,264207,DB00480,Lenalidomide
,29926217,AUC0-∞,"Subjects administered test lenalidomide and Revlimid® capsules in the fasting state had a Cmax of 564 ± 153 and 609 ± 121 ng/mL, respectively; an AUC0-t of 1660 ± 211 and 1660 ± 235 h ng/mL, respectively; and an AUC0-∞ of 1670 ± 210 and 1670 ± 237 h ng/mL, respectively.",Bioequivalence study of single-dose lenalidomide capsule vs. Revlimid® capsule in healthy Chinese males. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29926217/),[h·ng] / [ml],1670,264208,DB00480,Lenalidomide
,29926217,AUC0-∞,"Subjects administered test lenalidomide and Revlimid® capsules in the fasting state had a Cmax of 564 ± 153 and 609 ± 121 ng/mL, respectively; an AUC0-t of 1660 ± 211 and 1660 ± 235 h ng/mL, respectively; and an AUC0-∞ of 1670 ± 210 and 1670 ± 237 h ng/mL, respectively.",Bioequivalence study of single-dose lenalidomide capsule vs. Revlimid® capsule in healthy Chinese males. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29926217/),[h·ng] / [ml],1670,264209,DB00480,Lenalidomide
,29926217,Cmax,"In the fed state, the subjects had a Cmax of 389 ± 105 and 383 ± 101 ng/mL, respectively; an AUC0-t of 1770 ± 314 and 1740 ± 360 h ng/mL, respectively; and an AUC0-∞ of 1800 ± 316 and 1760 ± 362 h ng/mL, respectively.",Bioequivalence study of single-dose lenalidomide capsule vs. Revlimid® capsule in healthy Chinese males. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29926217/),[ng] / [ml],389,264210,DB00480,Lenalidomide
,29926217,Cmax,"In the fed state, the subjects had a Cmax of 389 ± 105 and 383 ± 101 ng/mL, respectively; an AUC0-t of 1770 ± 314 and 1740 ± 360 h ng/mL, respectively; and an AUC0-∞ of 1800 ± 316 and 1760 ± 362 h ng/mL, respectively.",Bioequivalence study of single-dose lenalidomide capsule vs. Revlimid® capsule in healthy Chinese males. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29926217/),[ng] / [ml],383,264211,DB00480,Lenalidomide
,29926217,AUC0-t,"In the fed state, the subjects had a Cmax of 389 ± 105 and 383 ± 101 ng/mL, respectively; an AUC0-t of 1770 ± 314 and 1740 ± 360 h ng/mL, respectively; and an AUC0-∞ of 1800 ± 316 and 1760 ± 362 h ng/mL, respectively.",Bioequivalence study of single-dose lenalidomide capsule vs. Revlimid® capsule in healthy Chinese males. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29926217/),[h·ng] / [ml],1770,264212,DB00480,Lenalidomide
,29926217,AUC0-t,"In the fed state, the subjects had a Cmax of 389 ± 105 and 383 ± 101 ng/mL, respectively; an AUC0-t of 1770 ± 314 and 1740 ± 360 h ng/mL, respectively; and an AUC0-∞ of 1800 ± 316 and 1760 ± 362 h ng/mL, respectively.",Bioequivalence study of single-dose lenalidomide capsule vs. Revlimid® capsule in healthy Chinese males. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29926217/),[h·ng] / [ml],1740,264213,DB00480,Lenalidomide
,29926217,AUC0-∞,"In the fed state, the subjects had a Cmax of 389 ± 105 and 383 ± 101 ng/mL, respectively; an AUC0-t of 1770 ± 314 and 1740 ± 360 h ng/mL, respectively; and an AUC0-∞ of 1800 ± 316 and 1760 ± 362 h ng/mL, respectively.",Bioequivalence study of single-dose lenalidomide capsule vs. Revlimid® capsule in healthy Chinese males. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29926217/),[h·ng] / [ml],1800,264214,DB00480,Lenalidomide
,29926217,AUC0-∞,"In the fed state, the subjects had a Cmax of 389 ± 105 and 383 ± 101 ng/mL, respectively; an AUC0-t of 1770 ± 314 and 1740 ± 360 h ng/mL, respectively; and an AUC0-∞ of 1800 ± 316 and 1760 ± 362 h ng/mL, respectively.",Bioequivalence study of single-dose lenalidomide capsule vs. Revlimid® capsule in healthy Chinese males. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29926217/),[h·ng] / [ml],1760,264215,DB00480,Lenalidomide
,19671864,Overall response rate,"Overall response rate was 42%, including three partial responses among nine bortezomib refractory patients.",Phase I study of vorinostat in combination with bortezomib for relapsed and refractory multiple myeloma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19671864/),%,42,267419,DB00480,Lenalidomide
,30862646,Overall response rate,Overall response rate was 62%; median duration of response was 18.7 months; median progression-free survival was 17.6 months.,A phase 1b study of isatuximab plus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30862646/),%,62,268793,DB00480,Lenalidomide
,30862646,duration of response,Overall response rate was 62%; median duration of response was 18.7 months; median progression-free survival was 17.6 months.,A phase 1b study of isatuximab plus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30862646/),,18,268794,DB00480,Lenalidomide
,30862646,progression-free survival,Overall response rate was 62%; median duration of response was 18.7 months; median progression-free survival was 17.6 months.,A phase 1b study of isatuximab plus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30862646/),month,17.6,268795,DB00480,Lenalidomide
,28092421,overall response rate,The overall response rate was 88.5%.,"Carfilzomib, lenalidomide and dexamethasone in patients with heavily pretreated multiple myeloma: A phase 1 study in Japan. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28092421/),%,88.5,271881,DB00480,Lenalidomide
